Aarvik Therapeutics
PrivateLast Round
Series 2
Sep 29, 2025
Total Funding Raised
$2M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aarvik Therapeutics is a biotechnology company that develops novel molecules with an improved therapeutic index for oncology targets using proprietary modular antibody platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aarvik Therapeutics Comparables
Compare Aarvik Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adcentrx Therapeutics | 84% | |
| Iksuda Therapeutics | 80% | |
| Lonza Group | 77% | |
Aarvik Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series 2 | Sep 29, 2025 | ||||
| Seed | Aug 23, 2021 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 80% MoM.
Aarvik Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aarvik Therapeutics's valuation, stock price, and market status.